297 related articles for article (PubMed ID: 37060468)
1. Molecular mechanisms augmenting resistance to current therapies in clinics among cervical cancer patients.
Das S; Babu A; Medha T; Ramanathan G; Mukherjee AG; Wanjari UR; Murali R; Kannampuzha S; Gopalakrishnan AV; Renu K; Sinha D; George Priya Doss C
Med Oncol; 2023 Apr; 40(5):149. PubMed ID: 37060468
[TBL] [Abstract][Full Text] [Related]
2. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
Lee SJ; Yang A; Wu TC; Hung CF
J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
[TBL] [Abstract][Full Text] [Related]
4. The burden of human papillomavirus infections and related diseases in sub-saharan Africa.
De Vuyst H; Alemany L; Lacey C; Chibwesha CJ; Sahasrabuddhe V; Banura C; Denny L; Parham GP
Vaccine; 2013 Dec; 31 Suppl 5(0 5):F32-46. PubMed ID: 24331746
[TBL] [Abstract][Full Text] [Related]
5. [Preventive vaccines and immunotherapy clinical trials against cervical cancer].
Valdespino-Gómez VM
Cir Cir; 2005; 73(1):57-69. PubMed ID: 15888272
[TBL] [Abstract][Full Text] [Related]
6. A Qualitative Study of Parental Knowledge and Perceptions of Human Papillomavirus and Cervical Cancer Prevention in Rural Central Java, Indonesia: Understanding Community Readiness for Prevention Interventions.
Spagnoletti BRM; Bennett LR; Wahdi AE; Wilopo SA; Keenan CA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2429-2434. PubMed ID: 31450917
[TBL] [Abstract][Full Text] [Related]
7. Recurrent or primary metastatic cervical cancer: current and future treatments.
Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
[TBL] [Abstract][Full Text] [Related]
8. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
9. Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer.
Wolford JE; Tewari KS
Expert Opin Drug Discov; 2018 May; 13(5):445-457. PubMed ID: 29463131
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
11. [Cervical cancer: Current situation and management in Morocco].
Belglaiaa E; Mougin C
Bull Cancer; 2019 Nov; 106(11):1008-1022. PubMed ID: 31606139
[TBL] [Abstract][Full Text] [Related]
12. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease.
Mboumba Bouassa RS; Prazuck T; Lethu T; Jenabian MA; Meye JF; Bélec L
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):613-627. PubMed ID: 28440679
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic approaches for HPV-caused cervical cancer.
Fatemi SA; Seifi N; Rasekh S; Amiri S; Moezzi SMI; Bagheri A; Fathi S; Negahdaripour M
Adv Protein Chem Struct Biol; 2022; 129():51-90. PubMed ID: 35305725
[TBL] [Abstract][Full Text] [Related]
14. Human Papillomavirus Induced Cervical and Oropharyngeal Cancers: From Mechanisms to Potential Immuno-therapeutic Strategies.
Saeed M; Faisal SM; Akhtar F; Ahmad S; Alreshidi MM; Kausar MA; Kazmi S; Saeed A; Adnan M; Ashraf GM
Curr Drug Metab; 2020; 21(3):167-177. PubMed ID: 32316888
[TBL] [Abstract][Full Text] [Related]
15. HPV: Molecular pathways and targets.
Gupta S; Kumar P; Das BC
Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
[TBL] [Abstract][Full Text] [Related]
16. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
17. Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer.
Nogueira-Rodrigues A; Melo AC; Werutsky G; Garces AH; Ferreira CG
Curr Cancer Drug Targets; 2016; 16(3):249-60. PubMed ID: 26577537
[TBL] [Abstract][Full Text] [Related]
18. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
19. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
[TBL] [Abstract][Full Text] [Related]
20. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]